Avenda Health

What Avenda Health does

Avenda Health, Inc. is a privately held Los Angeles-based health technology company founded in 2012 as a UCLA spinout with National Cancer Institute grant support. It develops Unfold AI, an FDA 510(k)-cleared (K221624) deep-learning platform that combines MRI imaging, fusion-biopsy results, pathology data, and clinical biomarkers (PSA, Gleason scores) into personalized 3D cancer estimation maps used to identify prostate tumor location and extent. The company's second core product is the FocalPoint System, an FDA-cleared soft tissue laser ablation device (with Breakthrough Device Designation) for in-office prostate cancer focal therapy under ultrasound guidance.

The company serves urologists, radiologists, and prostate cancer patients across academic medical centers (UCLA Health, UAB, University of Michigan Health) and community urology practices. It makes money through (a) a transaction-fee model for Unfold AI analyses billed under Category III CPT code 0898T with CMS national payment established in 2024, and (b) hardware sales of the FocalPoint ablation device. Go-to-market combines direct enterprise field sales with channel partnerships — notably integration with EDAP TMS's Focal One robotic HIFU platform and Perineologic's PrecisionPoint transperineal access system — and is supported by peer-reviewed clinical publications and presence at urology conferences (AUA, Focal Therapy Society, HLTH).

Name

Avenda Health

Legal name

Avenda Health, Inc.

Website

https://avendahealth.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Avenda Health is a Los Angeles-based health technology company that develops Unfold AI, an FDA-cleared deep-learning platform generating 3D prostate cancer maps, and the FocalPoint laser ablation system, serving urologists, radiologists, and prostate cancer patients at academic medical centers and community practices.

Ownership category

akta.pro rank

Product category

AI Healthcare Decision Support Software

NAICS

Software Publishers (513210)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industry

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

Keywords

• Prostate cancer AI
• Medical imaging software
• Cancer treatment planning
• Urology decision support
• Medical device software

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Unfold AI Analysis/Reimbursement: Fee-for-service model based on CPT code 0898T for non-invasive prostate cancer estimation maps. Healthcare providers bill using Category III code for AI-derived cancer visualization and physician interpretation services. Reimbursement determined by CMS Hospital Outpatient Prospective Payment System (OPPS) with APC classification for diagnostic tests.
2. FocalPoint System: Sale of soft tissue ablation medical device for in-office laser prostate cancer treatment. FDA cleared for soft tissue ablation. Revenue from device sales to urology practices and hospitals.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Avenda Health develops and sells FDA-cleared AI-based prostate cancer management products. Unfold AI is an FDA 510(k)-cleared decision-support software that combines MRI, fusion biopsy, pathology, and PSA biomarker data using deep learning to generate personalized 3D cancer estimation maps. The company also offers the FocalPoint System, an FDA-cleared soft tissue laser ablation device for in-office prostate cancer focal therapy under ultrasound guidance.

Product overview

Avenda Health offers a unified AI-powered prostate cancer care platform centered on Unfold AI and the FocalPoint System. Unfold AI is an FDA-cleared AI decision support platform that creates personalized 3D cancer maps by combining multi-modal patient data (MRI, pathology, biomarkers), enabling physicians to precisely visualize cancer extent and select appropriate treatment pathways. The FocalPoint System is a complementary FDA-cleared soft tissue laser ablation device used for in-office focal therapy. Together, these products enable a complete diagnostic-to-treatment workflow: Unfold AI identifies and maps cancer location and extent, then guides treatment decisions including whether FocalPoint ablation, surgery, radiation, or active surveillance is most appropriate for each patient's specific disease.

Differentiator

Problem solved

Functional benefit

Products and services

• Unfold AI FDA-cleared AI-powered prostate cancer mapping platform that uses deep learning to combine MRI, fusion biopsy, pathology, and PSA data into personalized 3D cancer estimation maps (Cancer Estimation Map / CEM) and an Encapsulation Confidence Score (ECS) to guide treatment planning for urologists, radiologists, and academic medical centers.
• FocalPoint System FDA-cleared soft tissue laser ablation device for in-office prostate cancer focal therapy delivered under ultrasound guidance, designed to use patient-specific AI-derived data to perform precise personalized ablation while preserving healthy tissue.

Quantifiable outcome

• Tumor identification sensitivity increased from 37% (MRI alone) to 97% with Unfold AI
• +6 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core.

• University of Michigan HealthcoreTechnology or Integration · 12 May 2026University of Michigan Health Weiser Center for Prostate Cancer adopted Unfold AI for prostate cancer mapping platform. First deployment in the Midwest, expanding AI-guided prostate cancer care access to one of nation's leading urologic oncology programs.
• Scionti Prostate Center / Halo Precision DiagnosticscoreTechnology or Integration · 12 November 2024Sarasota-based Scionti Prostate Center, a Halo Precision Diagnostics affiliate, deploying Unfold AI. Dr. Stephen Scionti specializes in HIFU, TULSA, and Cryoablation treatments with global recognition for image-guided ablation methods.
• EDAP TMScoreTechnology or Integration · 19 September 2024Collaboration to launch world's first AI-assisted Focal One® robotic HIFU procedures. Unfold AI patient-specific cancer maps integrate with Focal One's HIFUsion® software for personalized, precise ablation procedures. First procedures performed at UCLA.
• Kasraeian UrologycoreTechnology or Integration · 21 May 2024Jacksonville-based urology practice implementing Unfold AI for enhanced diagnostic precision and treatment planning. Partnership improves local access to cutting-edge prostate cancer care on Florida's Gulf Coast.
• Urology Associates (Maryland) / PrecisionPoint®coreTechnology or Integration · 23 October 2023Dr. Matthew Allaway's Urology Associates became one of the first practices in the country to integrate Unfold AI with PrecisionPoint® transperineal access system for in-office procedures. Collaboration enables combined biopsy and AI-guided treatment planning.
• BioscienceLAcoreStrategic or Co-development Partner · 19 April 2023Avenda Health serves as anchor tenant at BioscienceLA life sciences innovation hub in Los Angeles. Partnership provides funding, deployment resources, incubator spaces, and infrastructure for early-stage life sciences companies.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• RaySearch Laboratories: RaySearch Laboratories develops oncology treatment-planning and information-management software used in radiation therapy. It is comparable because Unfold AI also supports radiotherapy planning, although RaySearch operates across multiple cancer types and modalities.
• GE HealthCare: GE HealthCare supplies MRI, ultrasound, imaging AI, and biopsy-guidance technologies used in prostate-cancer diagnosis. It is a broad incumbent whose imaging and oncology platforms overlap with Avenda's core diagnostics and treatment-planning workflow.
• AngioDynamics: AngioDynamics offers the NanoKnife irreversible electroporation system, including prostate tissue-ablation applications that overlap with Avenda's focal-therapy strategy. It is a broader medtech incumbent rather than a specialist in AI-based cancer mapping.
• Tempus AI: Tempus AI combines clinical data, molecular testing, and analytics to support cancer diagnosis and treatment selection. It is a broad precision-oncology incumbent that overlaps with Avenda's use of multimodal patient data for prostate-cancer management.
• Intuitive Surgical: Intuitive Surgical's da Vinci platform is widely used for robot-assisted prostatectomy and other urologic procedures. It serves many of the same urologists and health systems, but competes more broadly in surgical treatment delivery than in diagnostic mapping.
• Siemens Healthineers: Siemens Healthineers provides MRI and AI-enabled imaging systems that support prostate lesion detection, biopsy planning, and oncology workflows. Its scale and installed imaging base make it a broad infrastructure and technology incumbent relevant to Unfold AI.

Direct peers

• Profound Medical: Profound Medical offers TULSA-PRO, a transurethral ultrasound system for MRI-guided ablation of prostate tissue. It is a direct focal-therapy comparator serving the same prostate-cancer treatment market, although it does not provide Avenda's multimodal cancer-estimation mapping.
• EDAP TMS: EDAP TMS commercializes the Focal One robotic HIFU system for prostate tissue ablation and is integrating Avenda's Unfold AI cancer maps into its treatment workflow. It directly overlaps in AI-guided focal therapy and shares the same urologist and prostate-cancer treatment customer base.
• KOELIS: KOELIS develops MRI/3D ultrasound fusion, prostate mapping, and biopsy-planning tools for urologists. Its products overlap directly with Unfold AI in prostate imaging, lesion localization, biopsy guidance, and treatment planning.

Emerging players

• ArteraAI: ArteraAI develops AI-derived biomarkers that help physicians predict prognosis and treatment benefit in localized prostate cancer. It competes in AI-enabled prostate treatment decision support, though its focus is molecular and clinical biomarker analysis rather than 3D imaging maps.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks4 records

Key highlights6 records

Customer concentration

• Xx.com/avendahealth
• LinkedInlinkedin.com/company/avenda-health

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avenda Health